Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V132
- Development stage
- Phase 1
- Lead developer
- Inmunotek
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
V132 is an investigational next-generation pneumococcal conjugate vaccine (PCV) being developed by Merck (MSD) for the prevention of invasive pneumococcal disease. It is designed to provide broader protection against *Streptococcus pneumoniae* serotypes compared to existing vaccines such as VAXNEUVANCE (V114) and CAPVAXIVE (V116). The vaccine utilizes conjugate technology where purified capsular polysaccharides from various pneumococcal serotypes are conjugated to a carrier protein to enhance immunogenicity, particularly in older adults. V132 is currently in early-stage clinical development, with Phase 1 trials evaluating its safety, tolerability, and immune response in healthy older participants.
Beyond the preview
Go deeper on V132.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V132.